Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Cancer is one of the deadliest non communicable diseases. Numerous anticancer
medications have been developed to target the molecular pathways driving cancer …

Under normal physiological conditions, cellular homeostasis is partly regulated by a balance
of pro-and anti-phagocytic signals. CD47, which prevents cancer cell phagocytosis by the …

Mantle cell lymphoma (MCL) is a heterogeneous disease with most patients following an
aggressive clinical course, whereas others having an indolent behavior. We conducted an …

WEE1 kinase is a key molecule in maintaining G2–cell-cycle checkpoint arrest for premitotic
DNA repair. Whereas normal cells repair damaged DNA during G1-arrest, cancer cells often …

The mechanisms driving therapeutic resistance and poor outcomes of mantle cell lymphoma
(MCL) are incompletely understood. We characterize the cellular and molecular …

Bruton's tyrosine kinase (BTK) is a proven target in mantle cell lymphoma (MCL), an
aggressive subtype of non-Hodgkin lymphoma. However, resistance to BTK inhibitors is a …

CD24 and its ligand Siglec-10 were described as an innate immune checkpoint in
carcinoma. Here, we investigated this axis in B-cell lymphoma by assessing CD24 …

Leukocyte-associated immunoglobulin (Ig)-like receptor 1 (LAIR1, CD305) belongs to the
family of immune-inhibitory receptors and is widely expressed on hematopoietic mature …

Mantle cell lymphoma (MCL) is a B-cell malignancy characterized by a poor response to
treatment and prognosis. Constitutive activation of different signaling pathways in subsets of …